Gilead CFO’s stake falls 1.83% after $468,660 sale

Gilead Sciences CFO Andrew Dickinson sold 3,000 shares on Thursday at an average price of $156.22, a $468,660 transaction disclosed in a Securities and Exchange Commission filing cited by American Banking News on Sunday.

The sale reduced Dickinson’s direct holding by 1.83% to 161,096 shares, valued at about $25.2 million at the transaction price. Gilead opened at $156.19 on Friday, compared with a 12-month range of $114.02 to $160.51.

The filing said the sale was made under a pre-arranged Rule 10b5-1 trading plan, a mechanism that allows corporate insiders to schedule trades in advance. Such plans can limit the signal investors draw from an insider transaction, though they do not remove disclosure requirements.

American Banking News also reported that insider Johanna Mercier sold 3,000 shares at the same average price under a pre-arranged Rule 10b5-1 plan. The article said both executives retained substantial holdings after the transactions.

The sale comes with Gilead trading above its 50-day moving average of $147.19 and two-hundred-day moving average of $137.29. The company’s market value was reported at $193.67 billion, with a beta of 0.31.

Gilead last reported quarterly results on Aug. 3, when it posted a loss of $6.75 a share, narrower than the consensus estimate for a $7.25 loss. Revenue was $7.80 billion, above analysts’ expectations of $7.40 billion and up 10.6% from a year earlier, according to the article.

MarketBeat data cited by American Banking News showed 23 analysts with Buy ratings and six with Hold ratings, with an average rating of Moderate Buy and an average target price of $159.33.

Source: Securities filing cited by American Banking News, Oct. 18, 2026